In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS buys partner ZymoGenetics for $840.6mm

Executive Summary

Bristol-Myers Squibb Co. has acquired publicly traded ZymoGenetics Inc. for $840.6mm, paying just over six times the large-molecule drug developer's 2009 sales. BMS is spending $9.75 (a 90% premium) for each of Zymo's 86.2mm shares outstanding.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies